RVL Pharmaceuticals plc Stock-Based Compensation
RVL Pharmaceuticals plc reported Stock-Based Compensation of $731.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2023-08-14
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for the quarter ending 2023-06-30 was $232.00K, a 80.81% decline year-over-year.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for the quarter ending 2023-03-31 was $499.00K, a 58.73% decline year-over-year.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for the quarter ending 2022-12-31 was $894.00K, a 10.78% decline year-over-year.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for the quarter ending 2022-09-30 was $758.00K, a 81.88% decline year-over-year.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for fiscal 2022 was $4.07M, a 46.41% decline from fiscal 2021.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for fiscal 2021 was $7.59M, a 54.19% increase from fiscal 2020.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for fiscal 2020 was $4.92M.
- RVL Pharmaceuticals plc share-based payment arrangement, noncash expense for fiscal 2018 was $1.97M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-06-30 | $232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $731.00K 10-Q · filed 2023-08-14 | $1.63M derived: sum of 3 quarters · filed 2023-08-14 | $2.38M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2023-03-31 | $499.00K 10-Q · filed 2023-05-11 | $1.39M derived: sum of 2 quarters · filed 2023-05-11 | $2.15M derived: sum of 3 quarters · filed 2023-05-11 | $3.36M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-12-31 | $894.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.65M derived: sum of 2 quarters · filed 2023-03-20 | $2.86M derived: sum of 3 quarters · filed 2023-08-14 | $4.07M 10-K · filed 2023-03-20 | ||||
| 2022-09-30 | $758.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.97M derived: sum of 2 quarters · filed 2023-08-14 | $3.18M 10-Q · filed 2022-11-10 | $4.18M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $2.42M 10-Q · filed 2023-08-14 | $3.42M derived: sum of 3 quarters · filed 2023-08-14 | $7.60M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $1.21M 10-Q · filed 2023-05-11 | $2.21M derived: sum of 2 quarters · filed 2023-05-11 | $6.39M derived: sum of 3 quarters · filed 2023-05-11 | $7.63M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $5.18M derived: sum of 2 quarters · filed 2023-03-20 | $6.42M derived: sum of 3 quarters · filed 2023-03-20 | $7.59M 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.42M derived: sum of 2 quarters · filed 2022-11-10 | $6.59M 10-Q · filed 2022-11-10 | $7.68M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.41M 10-Q · filed 2022-08-11 | $1.74M 10-Q · filed 2021-08-16 | $3.50M derived: sum of 3 quarters · filed 2022-08-11 | $5.57M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $1.18M 10-Q · filed 2022-05-12 | $2.27M derived: sum of 2 quarters · filed 2022-05-12 | $4.34M derived: sum of 3 quarters · filed 2022-05-12 | $5.00M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $3.16M derived: sum of 2 quarters · filed 2022-03-30 | $3.82M derived: sum of 3 quarters · filed 2022-03-30 | $4.92M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.73M derived: sum of 2 quarters · filed 2021-11-15 | $3.84M 10-Q · filed 2021-11-15 | $4.94M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $656.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.76M 10-Q · filed 2021-08-16 | $2.33M 10-Q · filed 2020-08-11 | $2.86M derived: sum of 3 quarters · filed 2021-09-08 | $4.20M derived: sum of 4 quarters · filed 2021-09-08 | |||
| 2020-03-31 | $1.11M 10-Q · filed 2021-05-13 | $2.21M derived: sum of 2 quarters · filed 2021-09-08 | $3.54M derived: sum of 3 quarters · filed 2021-09-08 | $4.87M derived: sum of 4 quarters · filed 2021-09-08 | ||||
| 2019-12-31 | $1.10M derived: 8-K 12 month − 10-Q 9 month · filed 2021-09-08 | $2.44M derived: sum of 2 quarters · filed 2021-09-08 | $3.76M derived: sum of 3 quarters · filed 2021-09-08 | $4.93M 8-K · filed 2021-09-08 | ||||
| 2019-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.66M derived: sum of 2 quarters · filed 2020-11-10 | $3.83M 10-Q · filed 2020-11-10 | $3.83M 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $2.50M 10-Q · filed 2020-08-11 | $2.50M 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $1.17M 10-Q · filed 2020-05-12 | $1.17M 10-Q · filed 2019-05-09 | ||||||
| 2018-12-31 | $1.97M 10-K · filed 2020-03-19 | $1.97M 10-K · filed 2019-03-28 |